Quinoline-2,3-dicarboxylic acid

We are Quinoline-2,3-dicarboxylic acid CAS:643-38-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 643-38-9
Product Name: Quinoline-2,3-dicarboxylic acid
Other Name:
Quinoline-2,3-dicarboxylic acid
Acridinic acid
Quinolinedicarboxylic acid
Chinolin-2,3-dicarbonsaeure
Acridinsaeure
2,3-Quinoline dicarboxylic acid
 
Density: 1.5±0.1 g/cm3
Boiling Point: 423.7±40.0 °C at 760 mmHg
Molecular Formula: C11H7NO4
Molecular Weight: 217.178
Flash Point: 210.0±27.3 °C
Exact Mass: 217.037506
PSA: 87.49000
LogP: 1.50
Vapour Pressure: 0.0±1.1 mmHg at 25°C
Index of Refraction: 1.720
 
Specification
Appearance: White solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Imazaquin CAS: 81335-37-7.
Be used as pesticide intermediate, mainly used in the synthesis of the herbicide Imazaquin.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Quinoline-2,3-dicarboxylic acid


Related News: The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.69411-68-3 The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.50889-46-8 At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.Benzyl (S)-(-)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate p-toluenesulfonic acid salt CAS:77497-97-3 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
1-Bromo-3,5-difluorobenzene View Details
Tripeptide-3 View Details
N-(2,6-Dimethylphenyl)chloroacetamide View Details
(S)-3-Acetylthio-2-methylpropionyl-L-proline manufacturer 4-(methylamino)-3-nitrobenzoyl chloride manufacturer 2-Ethylhexyl 4-(Dimethylamino)benzoate manufacturer 4-chlorobutanol manufacturer 2-Methoxy-4-methylpyridine manufacturer